Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TYMP | P19971 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25504803 | 1.00 | TK2 (0.50) | TK2ALDH1A1LMNAALBPOLB | |
| 5-Methyl-2'-Fluoroarauracil SCHEMBL139783 | 0.90 | TK2 (0.58) | TK2ALDH1A1LMNAALBPOLB | |
| Clevudine SCHEMBL9488300 | 0.90 | TK2 (0.58) | TK2ALDH1A1LMNAALBPOLB | |
| Clevudine SCHEMBL1981966 | 0.90 | TK2 (0.58) | TK2ALDH1A1LMNAALBPOLB | |
| Clevudine SCHEMBL24739180 | 0.90 | TK2 (0.58) | TK2ALDH1A1LMNAALBPOLB | |
| Clevudine SCHEMBL23397435 | 0.90 | TK2 (0.58) | TK2ALDH1A1LMNAALBPOLB | |
| Clevudine SCHEMBL766405 | 0.90 | TK2 (0.58) | TK2ALDH1A1LMNAALBPOLB | |
| Clevudine SCHEMBL24689944 | 0.90 | TK2 (0.58) | TK2ALDH1A1LMNAALBPOLB | |
| Clevudine SCHEMBL21577344 | 0.90 | TK2 (0.58) | TK2ALDH1A1LMNAALBPOLB | |
| Clevudine SCHEMBL21887421 | 0.90 | TK2 (0.58) | TK2ALDH1A1LMNAALBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | TK2 134/4885ALDH1A1 997/4885LMNA 2032/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | TK2 134/4885ALDH1A1 997/4885LMNA 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.